the satisfaction of customary closing conditions. There are no future contingent payments associated with the acquisition.
2024 Transactions
In December 2024, Merck closed an exclusive global license to develop, manufacture and commercialize MK-2010 (LM-299), a novel investigational PD-1/vascular endothelial growth factor (VEGF) bispecific antibody from LaNova Medicines Ltd (LaNova). Merck recorded a charge of $
588
million to
Research and development
expenses in 2024 for the upfront payment, which was made in January 2025. LaNova is also eligible to receive $
300
million upon technology transfer, which is anticipated to be completed in 2025, as well as future contingent developmental milestone payments of up to $
140
million, regulatory milestone payments of up to $
860
million and sales-based milestone payments of up to $
1.4
billion.
Also in December 2024, Merck closed an exclusive global license to develop, manufacture and commercialize MK-4082 (HS-10535), an investigational preclinical oral small molecule GLP-1 receptor agonist from Hansoh Pharma (Hansoh). Merck recorded a charge of $
112
million to
Research and development
expenses in 2024 for the upfront payment, which was made in February 2025. Hansoh is also eligible to receive future contingent
84
Table of Content
s
development-related milestone payments of up to $
115
million, regulatory milestone payments of up to $
315
million and sales-based milestone payments of up to $
1.47
billion, as well as tiered royalties ranging from a high-single-digit rate to a low-double-digit rate on future net sales of MK-4082 (HS-10535), if approved. Under the agreement, Hansoh may co-promote or solely commercialize MK-4082 (HS-10535) in Chinese mainland, Hong Kong and Macau, subject to certain conditions.
In September 2024, Merck acquired MK-1045 (formally CN201), a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from Curon Biopharmaceutical (Curon) for an upfront payment of $
700
million. In addition, Curon is eligible to receive future contingent developmental milestone payments of up to $
300
million and regulatory milestone payments of up to $
300
million. The transaction was accounted for as an asset acquisition. Merck recorded a charge of $
750
million (reflecting the upfront payment and other related costs) to
Research and development
expenses in 2024 related to the execution of the transaction. In connection with the agreement, Merck is also obligated to pay a third party future contingent developmental, regulatory and sales-based milestone payments of up to $
128
million in the aggregate, as well as tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales of MK-1045, if approved.
In July 2024, Merck acquired the aqua business of Elanco Animal Health Incorporated (Elanco aqua business) for total consideration of $
1.3
billion. The Elanco aqua business consists of an innovative portfolio of